STOCKHOLM, Sweden, Dec. 19, 2005 (PRIMEZONE) -- Diamyd Medical AB (OMX:DIAMB) today announced that is has reached an agreement with Protein Sciences Corporation, a Meriden, CT-based biopharmaceutical service company, for production of Diamyd(tm), its lead therapeutic diabetes vaccine. Under the terms of the agreement, Protein Sciences (PSC) will produce Diamyd Medical’s lead therapeutic diabetes vaccine for Phase III trials, as well as prepare to file an Investigational New Drug Application (IND) with the U.S. Food & Drug Administration (FDA). Diamyd Medical also is participating in Protein Sciences’ current round of financing, with a US$3 million investment.
